Details of the Drug Reposition

General Information of This Drug (ID: DMKFRWU)

Drug Name
Anetumab ravtansine   DMKFRWU
Synonyms Mesothelin-ADC
Drug Type
Antibody drug conjugate

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
Malignant pleural mesothelioma DIST2R60 2C26.0 Phase 2 [2]
Mesothelioma DISKWK9M 2C51.2 Phase 2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03926143) A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)